company background image
TGNA logo

Transgene DB:TGNA Stock Report

Last Price

€1.11

Market Cap

€111.2m

7D

0%

1Y

-40.0%

Updated

26 Mar, 2024

Data

Company Financials +

TGNA Stock Overview

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

TGNA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Transgene SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Transgene
Historical stock prices
Current Share Price€1.11
52 Week High€2.15
52 Week Low€1.01
Beta0.71
1 Month Change4.52%
3 Month Change-18.98%
1 Year Change-40.00%
3 Year Change-56.04%
5 Year Change-60.64%
Change since IPO-97.41%

Recent News & Updates

Recent updates

Shareholder Returns

TGNADE BiotechsDE Market
7D0%3.3%1.6%
1Y-40.0%35.8%6.4%

Return vs Industry: TGNA underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: TGNA underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is TGNA's price volatile compared to industry and market?
TGNA volatility
TGNA Average Weekly Movement5.5%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: TGNA's share price has been volatile over the past 3 months.

Volatility Over Time: TGNA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1979143Alessandro Rivahttps://www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TGNA fundamental statistics
Market cap€111.23m
Earnings (TTM)-€33.43m
Revenue (TTM)€8.91m

12.5x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TGNA income statement (TTM)
Revenue€8.91m
Cost of Revenue€31.56m
Gross Profit-€22.65m
Other Expenses€10.78m
Earnings-€33.43m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 27, 2024

Earnings per share (EPS)-0.33
Gross Margin-254.29%
Net Profit Margin-375.29%
Debt/Equity Ratio52.3%

How did TGNA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.